drugset / Trial / NCT02283749
BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases
Phase 2
Completed
5 enrolled
Angela Taber MD
Bayer · collabRhode Island Hospital · collabThe Miriam Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study patient's will receive the medicine Xofigo which is a radioactive drug that is FDA approved to treat prostate cancer that has spread to the bones. Xofigo has not previously been tested to treat lung cancer that has spread to the bones. Your doctors are studying the effects, good and bad, of Xofigo when used to treat lung cancer that has spread to the bones.
Timeline
- Start
- 2015-09
- Primary completion
- 2018-07-05
- Completion
- 2018-11-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Radium-223 dichloride | Other / unclassified | 0.05 mbq/kg | Intravenous |